JOHNSON & JOHNSON |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 149.5 USD | +0.23% |
|
+3.35% | -4.75% |
| Apr. 22 | J&J: EU green light for Carvykti in multiple myeloma | CF |
| Apr. 22 | Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating | MT |
Presenter SpeechChris Shibutani (Analysts)Welcome, everyone, to our highlight, final presentat...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
149.1
USD
Average target price
173.6
USD
Spread / Average Target
+16.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.75% | 359B | |
| +27.17% | 659B | |
| +27.68% | 557B | |
| +16.88% | 322B | |
| +9.66% | 297B | |
| +6.17% | 215B | |
| +5.37% | 210B | |
| -6.01% | 200B | |
| -8.37% | 149B | |
| -5.26% | 146B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Transcript : Johnson & Johnson Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-16-2022 10
